Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Has $17.31 Million Stake in Cellebrite DI Ltd. $CLBT

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,081,078 shares of the company’s stock after selling 18,637 shares during the quarter. Cellebrite DI accounts for approximately 1.3% of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD’s holdings, making the stock its 27th largest holding. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD’s holdings in Cellebrite DI were worth $17,308,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Cellebrite DI in the first quarter valued at about $60,939,000. Invesco Ltd. increased its position in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock valued at $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Phoenix Financial Ltd. increased its position in shares of Cellebrite DI by 153.5% in the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock valued at $32,232,000 after acquiring an additional 1,219,958 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Cellebrite DI in the first quarter valued at about $22,428,000. Finally, Royal Bank of Canada increased its position in Cellebrite DI by 11,705.0% during the first quarter. Royal Bank of Canada now owns 824,226 shares of the company’s stock worth $16,015,000 after buying an additional 817,244 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Trading Up 3.6%

CLBT stock opened at $18.42 on Friday. The stock has a 50-day moving average price of $17.56 and a 200-day moving average price of $16.93. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30. The firm has a market cap of $4.41 billion, a PE ratio of -24.24, a price-to-earnings-growth ratio of 3.23 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CLBT shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. Wall Street Zen raised Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. Lake Street Capital lowered their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.75.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.